Tezspire approved for self-administration in the EU in a new pre-filled pen
New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations.AstraZeneca’s Tezspire (tezepelumab) has received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. The CHMP opinion can be implemented without the need for a European Commission decision due to the nature of the Type-II label variation. The approval for self-administration was based on